CoChat

“LRRK2: Autophagy and Lysosomal Activity”

Open access
Madureira, Marta, Connor-Robson, Natalie, Wade-Martins, Richard · 2020 · Frontiers in Neuroscience
Cited by 137

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

) gene was identified as the most common genetic cause for Parkinson's disease (PD). The two most common mutations are the LRRK2-G2019S, located in the kinase domain, and the LRRK2-R1441C, located in the ROC-COR domain. While the LRRK2-G2019S mutation is associated with increased kinase activity, the LRRK2-R1441C exhibits a decreased GTPase activity and altered kinase activity. Multiple lines of evidence have linked the LRRK2 protein with a role in the autophagy pathway and with lysosomal activity in neurons. Neurons rely heavily on autophagy to recycle proteins and process cellular waste due to their post-mitotic state. Additionally, lysosomal activity decreases with age which can potentiate the accumulation of α-synuclein, the pathological hallmark of PD, and subsequently lead to the build-up of Lewy bodies (LBs) observed in this disorder. This review provides an up to date summary of the LRRK2 field to understand its physiological role in the autophagy pathway in neurons and related cells. Careful assessment of how LRRK2 participates in the regulation of phagophore and autophagosome formation, autophagosome and lysosome fusion, lysosomal maturation, maintenance of lysosomal pH and calcium levels, and lysosomal protein degradation are addressed. The autophagy pathway is a complex cellular process and due to the variety of LRRK2 models studied in the field, associated phenotypes have been reported to be seemingly conflicting. This review provides an in-depth discussion of different models to assess the normal and disease-associated role of the LRRK2 protein on autophagic function. Given the importance of the autophagy pathway in Parkinson's pathogenesis it is particularly relevant to focus on the role of LRRK2 to discover novel therapeutic approaches that restore lysosomal protein degradation homeostasis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnins.2020.00498

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 30 references

Research works printed but not linked: 121

  1. Alcalay, 2015, Glucocerebrosidase activity in Parkinson’s disease with and without GBA mutations., Brain, 138, 2648, 10.1093/brain/awv179 · DOI · Paper page
  2. Alegre-Abarrategui, 2009, LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model., Hum. Mol. Genet., 18, 4022, 10.1093/hmg/ddp346 · DOI · Paper page
  3. Antony, 2013, The hallmarks of Parkinson’s disease., FEBS J., 280, 5981, 10.1111/febs.12335 · DOI · Paper page
  4. Atashrazm, 2016, LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives., Clin. Pharmacol. Adv. Appl., 8, 177, 10.2147/CPAA.S102191 · DOI · Paper page
  5. Bahmad, 2017, Modeling human neurological and neurodegenerative diseases: from induced pluripotent stem cells to neuronal differentiation and its applications in neurotrauma., Front,. Mol. Neurosci., 10, 10.3389/fnmol.2017.00050 · DOI
  6. Bandyopadhyay, 2008, The Chaperone-mediated autophagy receptor organizes in dynamic protein complexes at the lysosomal membrane., Mol. Cell. Biol., 28, 5747, 10.1128/mcb.02070-07 · DOI · Paper page
  7. Bang, 2016, LRRK2 interferes with aggresome formation for autophagic clearance., Mol. Cell. Neurosci., 75, 71, 10.1016/j.mcn.2016.06.007 · DOI
  8. Beavan, 2013, Glucocerebrosidase mutations and the pathogenesis of Parkinson disease., Ann. Med., 45, 511, 10.3109/07853890.2013.849003 · DOI · Paper page
  9. Beilina, 2014, Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease., Proc. Natl. Acad. Sci. U.S.A., 111, 2626, 10.1073/pnas.1318306111 · DOI · Paper page
  10. Berwick, 2019, LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same., Mol. Neurodegener., 14, 1, 10.1186/s13024-019-0344-2 · DOI · Paper page
  11. Blauwendraat, 2020, Genetic modifiers of risk and age at onset in GBA associated Parkinson’s disease and Lewy body dementia., Brain, 143, 234, 10.1093/brain/awz350 · DOI · Paper page
  12. Bravo-San Pedro, 2013, The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway., Cell. Mol. Life Sci., 70, 121, 10.1007/s00018-012-1061-y · DOI · Paper page
  13. Caesar, 2015, Changes in actin dynamics and F-actin structure both in synaptoneurosomes of LRRK2(R1441G) mutant mice and in primary human fibroblasts of LRRK2(G2019S) mutation carriers., Neuroscience, 284, 311, 10.1016/j.neuroscience.2014.09.070 · DOI
  14. Chan, 2007, siRNA screening of the kinome identifies ULK1 as a multidomain modulator of autophagy., J. Biol Chem., 282, 25464, 10.1074/jbc.M703663200 · DOI · Paper page
  15. Chen, 2018, LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinson’s disease: a review Julie Y.H. Chan., J. Biomed. Sci., 25, 1, 10.1186/s12929-018-0454-0 · DOI
  16. Cherubini, 2018, Convergent pathways in Parkinson’s disease., Cell Tissue Res., 373, 79, 10.1007/s00441-017-2700-2 · DOI
  17. Cho, 2014, Leucine-rich repeat kinase 2 regulates Sec16A at ER exit sites to allow ER –Golgi export., EMBO J., 33, 2314, 10.15252/embj.201487807 · DOI
  18. Chu, 2009, Alterations in lysosomal and proteasomal markers in Parkinson’s disease: relationship to alpha-synuclein inclusions., Neurobiol. Dis., 35, 385, 10.1016/j.nbd.2009.05.023 · DOI · Paper page
  19. Chung, 2013, Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons., Science, 342, 983, 10.1126/science.1245296 · DOI · Paper page
  20. Colla, 2012, Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo., J. Neurosci., 32, 3301, 10.1523/JNEUROSCI.5368-11.2012 · DOI · Paper page
  21. Connor-Robson, 2019, An integrated transcriptomics and proteomics analysis reveals functional endocytic dysregulation caused by mutations in LRRK2., Neurobiol. Dis., 127, 512, 10.1016/j.nbd.2019.04.005 · DOI · Paper page
  22. Cookson, 2016, Cellular functions of LRRK2 implicate vesicular trafficking pathways in Parkinson’s disease., Biochem. Soc. Trans., 44, 1603, 10.1042/BST20160228 · DOI · Paper page
  23. Cookson, 2017, Mechanisms of mutant LRRK2 neurodegeneration., Adv. Neurobiol., 14, 227, 10.1007/978-3-319-49969-7_12 · DOI
  24. Deretic, 2011, Autophagy in immunity and cell-autonomous defense against intracellular microbes., Immunol. Rev., 240, 92, 10.1111/j.1600-065X.2010.00995.x · DOI · Paper page
  25. Dodson, 2014, Novel ethyl methanesulfonate (EMS)-induced null alleles of the Drosophila homolog of LRRK2 reveal a crucial role in endolysosomal functions and autophagy in vivo., Dis. Models Mech., 7, 1351, 10.1242/dmm.017020 · DOI · Paper page
  26. Dodson, 2012, Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning., Hum. Mol. Genet., 21, 1350, 10.1093/hmg/ddr573 · DOI · Paper page
  27. Dorsey, 2007, Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030., Neurology, 68, 384, 10.1212/01.wnl.0000247740.47667.03 · DOI · Paper page
  28. Eguchi, 2018, LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis., Proc. Natl. Acad. Sci. U.S.A., 115, E9115, 10.1073/pnas.1812196115 · DOI · Paper page
  29. Fernandes, 2016, ER Stress and autophagic perturbations lead to elevated extracellular α-Synuclein in GBA-N370S Parkinson’s iPSC-derived dopamine neurons., Stem Cell Rep., 6, 342, 10.1016/j.stemcr.2016.01.013 · DOI · Paper page
  30. Ghislat, 2013, Ca2+-sensor proteins in the autophagic and endocytic traffic., Curr. Protein Peptide Sci., 14, 97, 10.2174/13892037112139990033 · DOI
  31. Giaime, 2017, Age-dependent dopaminergic neurodegeneration and impairment of the autophagy-lysosomal pathway in LRRK-deficient mice., Neuron, 96, 796.e6, 10.1016/j.neuron.2017.09.036 · DOI · Paper page
  32. Giménez-Xavier, 2008, LC3-I conversion to LC3-II does not necessarily result in complete autophagy., Int. J. Mol. Med., 22, 781, 10.3892/ijmm_00000085 · DOI · Paper page
  33. Godena, 2014, Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations., Nat. Commun., 5, 10.1038/ncomms6245 · DOI · Paper page
  34. Gómez-Suaga, 2012, Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP., Hum. Mol. Genet., 21, 511, 10.1093/hmg/ddr481 · DOI · Paper page
  35. Guaitoli, 2016, First model of dimeric LRRK2: the challenge of unrevealing the structure of a multidomain Parkinson’s-associated protein., Biochem. Soc. Trans., 44, 1635, 10.1042/BST20160226 · DOI
  36. Han, 2012, Leucyl-tRNA synthetase is an intracellular leucine sensor for the mTORC1-signaling pathway., Cell, 149, 410, 10.1016/j.cell.2012.02.044 · DOI · Paper page
  37. Hardy, 2010, Genetic analysis of pathways to parkinson disease., Neuron, 68, 201, 10.1016/j.neuron.2010.10.014 · DOI · Paper page
  38. Härtlova, 2018, LRRK2 is a negative regulator of Mycobacterium tuberculosis phagosome maturation in macrophages., EMBO J., 37, 1, 10.15252/embj.201798694 · DOI · Paper page
  39. Healy, 2008, Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study., Lancet Neurol., 7, 583, 10.1016/S1474-4422(08)70117-0 · DOI · Paper page
  40. Henderson, 2019, LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice., Acta Neuropathol. Commun., 7, 1, 10.1186/s40478-019-0679-5 · DOI · Paper page
  41. Higashi, 2009, Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease., J. Neuropathol. Exp. Neurol., 68, 994, 10.1097/NEN.0b013e3181b44ed8 · DOI · Paper page
  42. Ho, 2018, LRRK2 impairs autophagy by mediating phosphorylation of leucyl-tRNA synthetase., Cell Biochem. and Func., 36, 431, 10.1002/cbf.3364 · DOI
  43. Ho, 2019, Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA)., Autophagy, 1, 10.1080/15548627.2019.1603545 · DOI · Paper page
  44. Hockey, 2015, Dysregulation of lysosomal morphology by pathogenic LRRK2 is corrected by TPC2 inhibition., J. Cell Sci., 128, 232, 10.1242/jcs.164152 · DOI · Paper page
  45. Hu, 2018, LRRK2 G2019S mutation inhibits degradation of α-synuclein in an in vitro model of Parkinson’s Disease., Curr. Med. Sci., 38, 1012, 10.1007/s11596-018-1977-z · DOI
  46. Hu, 2015, The endosomal-lysosomal system: from acidification and cargo sorting to neurodegeneration., Transl. Neurodegener., 4, 1, 10.1186/s40035-015-0041-1 · DOI · Paper page
  47. Johnson, 2019, Triggers, facilitators, and aggravators: redefining Parkinson’s Disease pathogenesis., Trends Neurosci., 42, 4, 10.1016/j.tins.2018.09.007 · DOI · Paper page
  48. Juárez-Flores, 2018, Exhaustion of mitochondrial and autophagic reserve may contribute to the development of LRRK2 G2019S -Parkinson’s disease., J. Transl. Med., 16, 1, 10.1186/s12967-018-1526-3 · DOI
  49. Kalogeropulou, 2018, P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity., Biochem. J., 475, 1271, 10.1042/BCJ20170699 · DOI
  50. Karuppagounder, 2016, LRRK2 G2019S transgenic mice display increased susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated neurotoxicity., J. Chem. Neuroanat., 76, 90, 10.1016/j.jchemneu.2016.01.007 · DOI
  51. Kimura, 2015, TRIM-mediated precision autophagy targets cytoplasmic regulators of innate immunity., J. Cell Biol., 210, 973, 10.1083/jcb.201503023 · DOI · Paper page
  52. Klein, 2012, Genetics of Parkinson’s Disease., Cold Spring Harbor Perspect. Med., 2, 10.1101/cshperspect.a008888 · DOI · Paper page
  53. Kluss, 2019, LRRK2 links genetic and sporadic Parkinson’s disease., Biochem. Soc. Trans., 47, 651, 10.1042/BST20180462 · DOI · Paper page
  54. Lee, 2017, LRRK2 in peripheral and central nervous system innate immunity: its link to Parkinson’s disease., Biochem. Soc. Trans., 45, 131, 10.1042/BST20160262 · DOI · Paper page
  55. Lee, 2013, Autophagic failure promotes the exocytosis and intercellular transfer of α-synuclein., Exp. Mol. Med., 45, 1, 10.1038/emm.2013.45 · DOI · Paper page
  56. Lewis, 2007, The R1441C mutation of LRRK2 disrupts GTP hydrolysis., Biochem. Biophys. Res. Commun., 357, 668, 10.1016/j.bbrc.2007.04.006 · DOI · Paper page
  57. Li, 2017, Structural basis of dual Ca 2+ /pH regulation of the endolysosomal TRPML1 channel., Nat. Struc. Mol. Biol., 24, 205, 10.1038/nsmb.3362 · DOI · Paper page
  58. Li, 2009, Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson’s disease., Nat. Neurosci., 12, 826, 10.1038/nn.2349 · DOI · Paper page
  59. Liu, 2016, P62 links the autophagy pathway and the ubiqutin-proteasome system upon ubiquitinated protein degradation., Cell. Mol. Biol. Lett., 21, 1, 10.1186/s11658-016-0031-z · DOI · Paper page
  60. MacLeod, 2006, The familial parkinsonism gene LRRK2 regulates neurite process morphology., Neuron, 52, 587, 10.1016/j.neuron.2006.10.008 · DOI · Paper page
  61. MacLeod, 2013, RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson’s Disease risk., Neuron, 77, 425, 10.1016/j.neuron.2012.11.033 · DOI · Paper page
  62. Mamais, 2018, Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson’s disease brains with Lewy body pathology., Brain Res., 1701, 75, 10.1016/j.brainres.2018.07.023 · DOI · Paper page
  63. Manzoni, 2017, The LRRK2-macroautophagy axis and its relevance to Parkinson’s disease., Biochem. Soc. Trans., 45, 155, 10.1042/BST20160265 · DOI · Paper page
  64. Manzoni, 2017, LRRK2 and autophagy., Adv. Neurobiol., 14, 89, 10.1007/978-3-319-49969-7_5 · DOI
  65. Manzoni, Inhibition of LRRK2 kinase activity stimulates macroautophagy., Biochim. Biophys. Acta Mol. Cell Rese., 1833, 2900, 10.1016/j.bbamcr.2013.07.020 · DOI · Paper page
  66. Manzoni, Pathogenic parkinson’s disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation., Biochem. Biophys. Res. Commun., 441, 862, 10.1016/j.bbrc.2013.10.159 · DOI · Paper page
  67. Manzoni, 2018, mTOR independent alteration in ULK1 Ser758 phosphorylation following chronic LRRK2 kinase inhibition., Biosci. Rep., 38, 1, 10.1042/BSR20171669 · DOI
  68. Manzoni, 2016, MTOR independent regulation of macroautophagy by Leucine Rich Repeat Kinase 2 via Beclin-1., Sci. Res., 6, 1, 10.1038/srep35106 · DOI · Paper page
  69. McGlinchey, 2015, Cysteine cathepsins are essential in lysosomal degradation of α-synuclein., Proc. Natl. Acad. Sci. U.S.A., 112, 9322, 10.1073/pnas.1500937112 · DOI · Paper page
  70. Meley, 2006, AMP-activated protein kinase and the regulation of autophagic proteolysis., J. Biol. Chem., 281, 34870, 10.1074/jbc.M605488200 · DOI · Paper page
  71. Mizushima, 2002, Autophagosome formation in mammalian cells., Cell Struc. Func., 27, 421, 10.1247/csf.27.421 · DOI · Paper page
  72. Mortiboys, 2010, Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2., Neurology, 75, 2017, 10.1212/WNL.0b013e3181ff9685 · DOI · Paper page
  73. Nichols, 2010, 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson’s disease-associated mutations and regulates cytoplasmic localization., Biochem. J., 404, 393, 10.1042/BJ20100483 · DOI · Paper page
  74. Noda, 1998, Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast., J. Biol. Chem., 273, 3963, 10.1074/jbc.273.7.3963 · DOI · Paper page
  75. Obergasteiger, 2019, Kinase inhibition of G2019S-LRRK2 restores autolysosome formation and function to reduce endogenous alpha-synuclein intracellular inclusions., BioRxiv, 10.1101/707273 · doi:10.1101/707273
  76. Obergasteiger, 2018, A new hypothesis for Parkinson’s disease pathogenesis: GTPase-p38 MAPK signaling and autophagy as convergence points of etiology and genomics., Mol. Neurodegener., 13, 1, 10.1186/s13024-018-0273-5 · DOI
  77. Outeiro, 2019, LRRK2, alpha-synuclein, and tau: partners in crime or unfortunate bystanders?, Biochem. Soc. Trans., 47, 827, 10.1042/bst20180466 · DOI
  78. Paisán-Ruíz, 2004, Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease., Neuron, 44, 595, 10.1016/j.neuron.2004.10.023 · DOI · Paper page
  79. Pan, 2017, Parkinson’s disease-associated LRRK2 hyperactive kinase mutant disrupts synaptic vesicle trafficking in ventral midbrain neurons., J. Neurosci., 37, 11366, 10.1523/JNEUROSCI.0964-17.2017 · DOI · Paper page
  80. Parisiadou, 2014, LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity., Nat. Neurosci., 17, 367, 10.1038/nn.3636 · DOI · Paper page
  81. Park, 2016, Interplay between leucine-rich repeat kinase 2 (LRRK2) and p62/SQSTM-1 in Selective Autophagy., PLoS One, 11, 10.1371/journal.pone.0163029 · DOI
  82. Plowey, 2008, Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells., J. Neurochem., 105, 1048, 10.1111/j.1471-4159.2008.05217.x · DOI · Paper page
  83. Polymeropoulos, 1997, Mutation in the α-synuclein gene identified in families with Parkinson’s disease., Science, 276, 2045, 10.1126/science.276.5321.2045 · DOI · Paper page
  84. Pupyshev, 2018, Suppression of autophagy in the brain of transgenic mice with overexpression of A53T-mutant α-synuclein as an early event at synucleinopathy progression., Neurosci. Lett., 672, 140, 10.1016/j.neulet.2017.12.001 · DOI
  85. Ryan, 2013, Isogenic human iPSC Parkinson’s model shows nitrosative stress-induced dysfunction in MEF2-PGC1α transcription., Cell, 155, 10.1016/j.cell.2013.11.009 · DOI · Paper page
  86. Saez-Atienzar, 2014, The LRRK2 inhibitor GSK2578215A induces protective autophagy in SH-SY5Y cells: involvement of Drp-1-mediated mitochondrial fission and mitochondrial-derived ROS signaling., Cell Death Dis., 5, 1, 10.1038/cddis.2014.320 · DOI · Paper page
  87. Saha, 2015, Mutations in LRRK2 potentiate age-related impairment of autophagic flux., Mol. Neurodegener., 10, 10.1186/s13024-015-0022-y · DOI · Paper page
  88. Sánchez-Danés, 2012, Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson’s disease., EMBO Mol. Med., 4, 380, 10.1002/emmm.201200215 · DOI · Paper page
  89. Sanyal, 2020, Lysosome and inflammatory defects in GBA1 -mutant astrocytes are normalized by LRRK2 inhibition., Mov. Disord., 27994, 10.1002/mds.27994 · DOI · Paper page
  90. Schapansky, 2018, Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons., Neurobiol. Dis., 111, 26, 10.1016/j.nbd.2017.12.005 · DOI · Paper page
  91. Schapansky, 2015, The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson’s disease., Neuroscience, 302, 74, 10.1016/j.neuroscience.2014.09.049 · DOI · Paper page
  92. Schneider, 2017, Neuropathology of genetic synucleinopathies with parkinsonism: review of the literature., Mov. Disord., 32, 1504, 10.1002/mds.27193 · DOI · Paper page
  93. Shani, 2019, Physiological and pathological roles of LRRK2 in the nuclear envelope integrity., Hum. Mol. Genet., 28, 3982, 10.1093/hmg/ddz245 · DOI
  94. Singleton, 2013, The genetics of Parkinson’s disease: progress and therapeutic implications., Mov. Disord., 28, 14, 10.1002/mds.25249 · DOI · Paper page
  95. Sloan, 2016, LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function., Hum. Mol. Genet., 25, 951, 10.1093/hmg/ddv628 · DOI · Paper page
  96. Smith, 2005, Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity., Hum. Mol. Gene., 14, 3801, 10.1093/hmg/ddi396 · DOI · Paper page
  97. Spillantini, 1997, α-Synuclein in lewy bodies., Nature, 388, 839, 10.1038/42166 · DOI · Paper page
  98. Steger, 2016, Phosphoproteomics reveals that Parkinson’s disease kinase LRRK2 regulates a subset of Rab GTPases., eLife, 5, 1, 10.7554/eLife.12813.001 · doi:10.7554/elife.12813.001
  99. Su, 2015, Threonine 56 phosphorylation of Bcl-2 is required for LRRK2 G2019S-induced mitochondrial depolarization and autophagy., Biochim. Biophys. Acta Mol. Basis Dis., 1852, 12, 10.1016/j.bbadis.2014.11.009 · DOI · Paper page
  100. Su, 2013, Inhibition of excessive mitochondrialfissionreduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation., Hum. Mol. Genet., 22, 4545, 10.1093/hmg/ddt301 · DOI · Paper page
  101. Taguchi, 2017, Glucosylsphingosine promotes α-synuclein pathology in mutant GBA-associated parkinson’s disease., J. Neurosci., 37, 9617, 10.1523/JNEUROSCI.1525-17.2017 · DOI · Paper page
  102. Tong, 2012, Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway., Mol. Neurodegener., 7, 1, 10.1186/1750-1326-7-222230652 · doi:10.1186/1750-1326-7-222230652
  103. Tong, 2010, Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged mice., Proc. Natl. Acad. Sci. U. S.A., 107, 9879, 10.1073/pnas.1004676107 · DOI · Paper page
  104. Tsika, 2014, Conditional expression of Parkinson’s disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration., Neurobiol. Dis., 71, 345, 10.1016/j.nbd.2014.08.027 · DOI
  105. Volpicelli-Daley, 2016, G2019s-LRRK2 expression augments α-synuclein sequestration into inclusions in neurons., J. Neurosci., 36, 7415, 10.1523/JNEUROSCI.3642-15.2016 · DOI · Paper page
  106. Wallings, 2019, LRRK2 interacts with the vacuolar-type H+-ATPase pump a1 subunit to regulate lysosomal function., Hum. Mol. Genet., 28, 2696, 10.1093/hmg/ddz088 · DOI · Paper page
  107. Wallings, 2015, Cellular processes associated with LRRK2 function and dysfunction., FEBS J., 282, 2806, 10.1111/febs.13305 · DOI · Paper page
  108. Wallings, 2019, LRRK2 regulation of immune-pathways and inflammatory disease., Biochem. Soc. Trans., 47, 1581, 10.1042/BST20180463 · DOI · Paper page
  109. Walter, 2019, Neural stem cells of Parkinson’s Disease Patients exhibit aberrant mitochondrial morphology and functionality., Stem Cell Rep., 12, 878, 10.1016/j.stemcr.2019.03.004 · DOI · Paper page
  110. Wang, 2015, Alpha-synuclein toxicity in the early secretory pathway: how it drives neurodegeneration in parkinsons disease., Front. Neurosci., 9, 10.3389/fnins.2015.00433 · DOI
  111. Wang, 2017, Destructive cellular paths underlying familial and sporadic Parkinson disease converge on mitophagy., Autophagy, 13, 1998, 10.1080/15548627.2017.1327511 · DOI
  112. Wang, 2012, LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1., Hum. Mol. Genet., 21, 1931, 10.1093/hmg/dds003 · DOI · Paper page
  113. Xilouri, 2013, α-Synuclein and protein degradation systems: a reciprocal relationship., Mol. Neurobiol., 47, 537, 10.1007/s12035-012-8341-2 · DOI · Paper page
  114. Yahalom, 2019, Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson’s disease: risk estimates and genotype-phenotype correlations., Park. Relat. Disord., 62, 179, 10.1016/j.parkreldis.2018.12.014 · DOI
  115. Ysselstein, 2019, LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson’s disease patients., Nat. Commun., 10, 1, 10.1038/s41467-019-13413-w · DOI · Paper page
  116. Yue, 2015, Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice., Neurobiol. Dis., 78, 172, 10.1016/j.nbd.2015.02.031 · DOI · Paper page
  117. Yun, 2015, An early endosome regulator. Rab5b, is an LRRK2 kinase substrate., J. Biochem., 157, 485, 10.1093/jb/mvv005 · DOI · Paper page
  118. Zambon, 2019, Cellular α-synuclein pathology is associated with bioenergetic dysfunction in Parkinson’s iPSC-derived dopamine neurons., Hum. Mol. Genet., 28, 2001, 10.1093/hmg/ddz038 · DOI · Paper page
  119. Zeng, 2018, Cellular and molecular basis of neurodegeneration in Parkinson disease., Front. Aging Neurosci., 10, 10.3389/fnagi.2018.00109 · DOI · Paper page
  120. Zhou, 2016, Autophagy activation prevents sevoflurane-induced neurotoxicity in H4 human neuroglioma cells., Acta Pharmacol. Sin., 37, 580, 10.1038/aps.2016.6 · DOI
  121. Zimprich, 2004, Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology., Neuron, 44, 601, 10.1016/j.neuron.2004.11.005 · DOI · Paper page

Cited by

See all 137

Metadata

Authors
Madureira, M., Connor-Robson, N., & Wade-Martins, R.
Venue
Frontiers in Neuroscience
Published
2020-05-25
Volume
14
Pages
498-498
ISSN
1662-453X (ISSN-L)
OpenAlex
W3027854502
Cited by
137
References
30
FWCI
6.21
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: “LRRK2: Autophagy and Lysosomal Activity”. https://app.cochat.ai/papers/10.3389/fnins.2020.00498
The paper
Madureira, M., Connor-Robson, N., & Wade-Martins, R. (2020). “LRRK2: Autophagy and Lysosomal Activity”. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2020.00498

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.